Several other brokerages also recently weighed in on BAYN. Credit Suisse Group set a €70.00 ($81.40) target price on shares of Bayer and gave the company a buy rating in a report on Wednesday, July 31st. DZ Bank reaffirmed a neutral rating on shares of Bayer in a report on Wednesday, July 31st. Deutsche Bank set a €70.00 ($81.40) target price on shares of Bayer and gave the company a neutral rating in a report on Friday, August 9th. Nord/LB set a €56.00 ($65.12) target price on shares of Bayer and gave the company a neutral rating in a report on Tuesday, July 30th. Finally, Warburg Research set a €61.00 ($70.93) target price on shares of Bayer and gave the company a neutral rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of €81.43 ($94.69).
Shares of FRA:BAYN opened at €67.72 ($78.74) on Tuesday. The firm’s 50-day simple moving average is €60.68 and its 200-day simple moving average is €60.97. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.